Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023

Three poster presentations to highlight clinical and preclinical data across Athira’s pipeline of neuroprotective therapeutic candidates

BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that three poster presentations will be delivered in-person at the upcoming Alzheimer’s Association International Conference (AAIC) 2023, to be held July 16 – 20, 2023, virtually and in Amsterdam, Netherlands. The presentations will highlight data from clinical and preclinical research of fosgonimeton in Alzheimer’s disease, and preclinical data of ATH-1105 in models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

AAIC Presentation Details:

Title: Fosgonimeton, a small-molecule positive modulator of the HGF/MET system, attenuates amyloid-beta-mediated toxicity in primary neuron cultures
Session: P2-05 Basic Science and Pathogenesis: Molecular and Cell Biology
Poster Number: 80009
Date/Time: Monday, July 17, 2023: 8:45 AM – 4:15 PM CEST
Presenter: Sherif Reda, PhD, Associate Director, Discovery Biology, Athira Pharma

Title: Biomarker analyses from the phase 2, randomized, placebo-controlled ACT-AD and open-label extension clinical trials of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease
Session: P4-06 Biomarkers: Biomarkers (non-neuroimaging)
Poster Number: 79759
Date/Time: Wednesday, July 19, 2023: 8:45 AM – 4:15 PM CEST
Presenter: Hans Moebius, MD, PhD, Chief Medical Officer, Athira Pharma

Title: ATH-1105, a small-molecule positive modulator of the HGF/MET system, is neuroprotective and attenuates TDP-43 protein pathology in ALS and frontotemporal dementia-relevant preclinical models
Session: P4-05 Basic Science and Pathogenesis: Molecular and Cell Biology
Poster Number: 80041
Date/Time: Wednesday, July 19, 2023: 8:45 AM – 4:15 PM CEST
Presenter: Jewel Johnston, PhD, Director, In Vivo Pharmacology, Athira Pharma

Full abstracts will be available to registered AAIC attendees. Access more information about AAIC 2023 here.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis (ALS). For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.